InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Lutetium-177 Market Size, Share & Trends Analysis Report By Application (Oncology, Non-Oncology), Type (No-Carrier-Added (NCA) Lu-177, Carrier-Added (CA) Lu-177), Product Type (Approved Drugs, Pipeline Drugs, Investigational Drugs), Scale of Operation (Preclinical, Clinical, Commercial), End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research Institutions/CROs), Production(Reactor-Based, Cyclotron-Based), Technology (Targeting Ligands, Production Innovations, Combination Therapies)- Market Outlook And Industry Analysis 2034″
According to the latest research by InsightAce Analytic, the Lutetium-177 Market is valued at USD 2.11 Bn in 2024, and it is expected to reach USD 7.41 Bn by the year 2034, with a CAGR of 11.6 during the forecast period of 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3024
Lutetium-177 (Lu-177) is a beta-emitting radioisotope utilized in targeted radionuclide therapy for the treatment of various cancers. It is produced through two primary methods: the direct route, involving the irradiation of Lu-176, which yields carrier-added (c.a.) Lu-177 containing isotopic impurities; and the indirect route, where Yb-176 is irradiated to generate non-carrier-added (n.c.a.) Lu-177, resulting in a higher-purity product with enhanced therapeutic efficacy.
As a theranostic agent, Lu-177 offers both diagnostic and therapeutic capabilities. It is particularly effective in managing malignancies such as neuroendocrine tumors and prostate cancer by enabling precise tumor localization through imaging, followed by targeted radiation delivery to eradicate cancer cells with minimal impact on surrounding healthy tissue. This dual functionality enhances treatment accuracy and improves clinical outcomes.
The global Lu-177 market is experiencing rapid growth, driven by the rising incidence of cancer and increasing adoption of targeted radiopharmaceutical therapies. The market is further supported by advancements in radiolabeling techniques and improved accessibility to nuclear medicine infrastructure.
Strategic collaborations among pharmaceutical companies, research institutions, and healthcare providers are significantly contributing to the market’s expansion. For example, in June 2024, Curium entered into a long-term agreement with the Institut Laue-Langevin (ILL) to scale up the production of non-carrier-added Lu-177.
This partnership aims to ensure a stable supply of the isotope for clinical applications, with the goal of treating a substantial number of cancer patients globally over the next five years. Such initiatives underscore the growing importance of Lu-177 in advancing personalized oncology therapies.
List of Prominent Players in the Lutetium-177 Market:
- Novartis AG
- Curium
- Telix Pharmaceuticals
- ITM Isotope Technologies
- Eli Lilly (via POINT Biopharma)
- Radiopharm Theranostics
- Advanced Accelerator Applications (AAA)
- Evergreen Theragnostics
- Nusano Inc.
- Nordic Nanovector
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics: Lutetium-177 (Lu-177)
Drivers:
The Lutetium-177 (Lu-177) market is primarily driven by the rising demand for targeted radiotherapy, particularly in the treatment of neuroendocrine tumors and prostate cancer. Lu-177’s high therapeutic specificity and reduced systemic side effects make it an attractive option in oncology.
The increasing adoption of targeted radionuclide therapies is accelerating market growth, further supported by advancements in radiopharmaceutical technologies that enhance production efficiency, delivery mechanisms, and imaging capabilities. Additionally, favorable regulatory policies and government funding for cancer research and nuclear medicine have streamlined approval processes and facilitated broader clinical adoption, contributing to market expansion.
Challenges:
Despite its promising outlook, the Lu-177 market faces several challenges. The complex and resource-intensive manufacturing process, which relies on enriched ytterbium, imposes limitations on production capacity and escalates costs. Supply chain constraints and regulatory compliance requirements also present significant barriers, limiting scalability and creating operational inefficiencies for industry stakeholders.
Regional Trends:
North America dominates the global Lu-177 market, supported by a well-established healthcare infrastructure, strong R&D capabilities, and a favorable regulatory environment. The presence of advanced oncology treatment centers and leading pharmaceutical firms fosters innovation and the rapid uptake of Lu-177-based therapies.
Moreover, substantial government investment in cancer research and domestic production capabilities—such as SHINE Technologies’ facility in Wisconsin—enhance supply chain resilience and reduce dependence on international imports. The region’s high cancer burden, with an estimated 2,001,140 new cases and 611,720 deaths projected in the U.S. for 2024, further amplifies demand for advanced, targeted treatment modalities like Lu-177.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3024
Recent Developments:
- In April 2024, The FDA approved Lutetium Lu 177 dotatate (Lutathera) for pediatric patients (12+) with SSTR-positive GEP-NETs, including foregut, midgut, and hindgut tumors. It had previously received approval for adults in 2018.
- In March 2022, The FDA approved Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had previously received androgen receptor pathway inhibition and taxane-based chemotherapy.
Segmentation of Trusted Platform Module Market-
By Application:
- Oncology
- mCRPC
- NETs
- RCC
- Other Cancers
- Non-Oncology
- Arthritis
- Other
By Type:
- Carrier-Added Lutetium-177
- No-Carrier-Added Lutetium-177
By Product Type:
- Approved Drugs
- Pluvicto (Pro)
- Lutathera (Pro)
- Pipeline Drugs
- Investigational Drugs
By Scale of Operation:
- Preclinical
- Clinical
- Commercial
By End-user:
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Research Institutions/CROs
By Production:
- Reactor-Based
- Cyclotron-Based
By Technology:
- Targeting Ligands
- Production Innovations
- Combination Therapies
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
